Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0348321 (Haemophilus)
 15,372 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The authors studied, with the Autobac machine, the kinetics of antibacterial activity of fosfomycin against Staphylococcus aureus, Streptococcus D' Streptococcus pneumoniae, Neisseria meningitidis, Acinetobactor lwoffi, Haemophilus influenzae, Salmonella typhimurium, Escherichia coli, Proteus rettgeri, Klebsiella pneumoniae, Serratia marcescens and Pseudomonas aeruginosa. A correlation appears between the kinetics of fosformycin antibacterial action and the microbial growth rate.
 ...
PMID:[Antibacterial kinetics of fosfomycin (author's transl)]. 54 59

Cefamandole, a new cephalosporin antibiotic, has greater activity against common pathogens, including Escherichia coli, Haemophilus influenzae, and Proteus (including indole-positive strains), than available cephalosporin drugs. We have evaluated the safety and pharmacokinetics of this drug in 30 infants and children. Blood levels and urinary excretion of the drug were similar to those previously found in adults. The only side effects were mild and transient elevation of serum glutamic oxalacetic transaminase in 12 patients and of blood urea nitrogen in 1 patient in whom serum creatinine remained normal and unchanged.
 ...
PMID:Pharmacokinetics and safety of cefamandole in infants and children. 57 Mar 72

Ninety-four patients with acquired tracheobronchomalacia were followed up between 1967-1977, for an average of 5.2 years. Fifty-six were still alive at the end of the period, and 47 of these were reexamined. Twenty-one patients had retired on pensions for lung disease. Of the 36 patients who underwent rebronchoscopy, tracheomalacia alone was seen in 3 and tracheobrochomalacia in 33. Six out of the 9 cases of tracheomalacia and all the 5 cases of bronchomalacia had developed into tracheobronchomalacia. The malacia was mild in 6 (17%), moderate in 8 (22%) and severe in 22 (61%), against the figures of the preceding bronchoscopy: 13 (36%), 17 (47%) and 6 (17%), respectively. Mild bronchitic changes were seen in 9 (25%) and severe in 22 (61%) bacterial cultures grew Haemophilus, Proteus mirabilis and Klebsiella, and the culture was positive on 8 occasions (22%). A fungal culture of the bronchial aspirate was positive in 9 cases (25%). No pronounced eosinophilia on the bronchial mucosa was observed.
 ...
PMID:Acquired tracheobronchomalacia. A bronchological follow-up study. 61 25

The antimicrobial activity of cefaclor, a new orally administered cephalosporin derivative, was studied in vitro against a variety of Gram-positive and Gram-negative clinical isolates. Both penicillin-resistant and penicillin-susceptible strains of Staphylococcus aureus were susceptible to cefaclor, with mean MICs of 1.44 and 0.93 microgram/ml, respectively. However, the MBC for penicillin-resistant S. aureus was higher than that for the penicillin-susceptible strains. All strains of Streptococcus pyogenes, Streptococcus viridans, and Streptococcus pneumoniae tested were highly susceptible to cefaclor; all strains of Streptococcus faecalis were highly resistant to cefaclor. Strains of Escherichia coli, Klebsiella sp., Proteus mirabilis, and Hemophilus influenzae were susceptible to cefaclor. Eighty per cent of strains of H. influenzae were inhibited by 5 micrograms/ml of cefaclor. Most strains of Enterobacter sp., indole-positive Proteus, Pseudomonas sp., and Serratia sp. were resistant to cefaclor.
 ...
PMID:Antimicrobial activity in vitro of cefaclor, a new oral cephalosporin. 62 78

The in vitro activity of cefaclor against 556 clinical isolates of gram-positive and gram-negative bacteria was compared with that of other cephalosporins. Cefaclor had activity similar to that of cephalexin against gram-positive bacteria. It showed greater activity against Haemophilus strains than did cephalexin and inhibited beta-lactamase-producing Haemophilus isolates. Cefaclor was more active than cephalexin or cephalothin against Escherichia coli, Salmonella, and Shigella isolates but did not act against Serratia, Acinetobacter, indole-positive Proteus, or Bacteroides isolates. Cefaclor was resistant to type III (TEM) beta-lactamases but was destroyed by type I beta-lactamases and, to a lesser degree, by type IV and type V beta-lactamases.
 ...
PMID:Cefaclor: in vitro spectrum of activity and beta-lactamase stability. 66 90

SQ 14,359 is a new cephamycin-type (7alpha-OCH3) antibiotic belonging to a series containing a 7alpha-ureidoacetyl substituent. The compound is the most potent extended spectrum derivative of this type yet reported, surpassing CS-1170 and cefoxitin by a wide margin. This activity in vitro which extends throughout the Enterobacteriaceae is particularly prominent against Gram-negative organisms that are producers of "cephalosporinase-type" beta-lactamases such as Enterobacter, Serratia, Citrobacter and indole-positive Proteus species. Superior activity also is demonstrated in vitro against streptococci, beta-lactamase-producing staphylococci, Haemophilus influenzae, Neisseria gonorrhoeae, and many Gram-negative pathogens resistant to aminoglycoside antibiotics. Experimental chemotherapeutic studies have confirmed these observations in wound and selected systemic infections in mice as well as acute pyelonephritis and meningitis in rats. The pharmacokinetics for each drug including antibiotic bound to serum was similar in both mice and rats. The pharmacokinetic profile in blood and cerebrospinal fluid favored SQ 14,359.
 ...
PMID:Cephamycin derivatives: comparison of the in vitro and in vivo antibacterial activities of SQ 14,359, CS-1170, and cefoxitin. 71 11

SCE-963 {7beta-[2-(2-aminothiazol-4-yl)acetamido]-3-[({1-(2-dimethylaminoethyl)- 1H-tetrazol-5-yl}thio)methyl]-ceph-3-em-4-carboxylic acid}, a new semisynthetic cephalosporin, showed excellent antibacterial activity against gram-positive and gram-negative bacteria, including Haemophilus influenzae, indole-positive Proteus, Enterobacter species, and Citrobacter freundii. The minimum inhibitory concentrations of SCE-963 against most strains of clinically isolated Escherichia coli, Klebsiella pneumoniae, H. influenzae, and Proteus mirabilis were within the range of 0.2 to 0.78 mug/ml. These activities were about 10 times more potent than those of cefazolin, cephaloridine, and cephalothin. Variations in pH, addition of horse serum, and type of growth medium had no significant effect on the activity of the cephalosporin, but the inoculum size elicited a considerable effect on the activity of beta-lactamase-producing strains of bacteria. SCE-963 exerted bactericidal and bacteriolytic effects on Staphylococcus aureus and E. coli. The pronounced in vitro activity was reflected in the remarkable protection in mice infected with a wide range of gram-negative bacteria, such as E. coli, K. pneumoniae, P. mirabilis, Proteus vulgaris, Proteus morganii, and Proteus rettgeri. The protective effects of SCE-963 in mice infected with E. coli, K. pneumoniae, and P. vulgaris varied according to the challenge dose. The activity of SCE-963 was far more potent when the drug was administered parenterally rather than orally.
 ...
PMID:SCE-963, a new broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. 71 54

A prospective clinical and bacteriological review of the pattern of bacterial infections and chemotherapy among 1931 patients admitted to University College Hospital, Ibadan, between July and September, 1976, showed that 394 patients (20%) had bacterial infections, but 940 patients (49%) received antimicrobial chemotherapy. Thus 58% of the patients were treated either prophylactically or without bacteriological confirmation of infection. Infections of the respiratory tract were commonest (28%), followed closely by wound infections (26%). Septicaemia accounted for 20% of all infections and this was particularly common among children. There was a preponderance of infections due to gram-negative bacteria (69%), with Klebsiella spp. being the most frequently encountered. Among the gram-positive organisms, Staphylococcus aureus accounted for the majority of the infections, particularly infections of wounds, while Salmonellae were responsible for the majority of septicaemias, except among young children, where Klebsiella spp. were predominant. Approximately 90% of urinary tract infections were caused by Klebsiella, Escherichia coli and Proteus spp. Almost all the patients with meningitis were children (93%) and the commonest infecting organisms were Haemophilus influenzae and Streptococcus pneumoniae. The most commonly used antibiotics (penicillin, streptomycin and ampicillin) did not bear a close relationship to the sensitivity patterns of bacteria causing infections in the hospital. Comparison of the bacterial sensitivity patterns for 1963, 1967, 1974 and 1976 showed that the current usage of antibiotics had led over the years to increasing proportions of resistant organisms.
 ...
PMID:Bacterial infections, sensitivity patterns, and chemotherapy among hospital patients in the tropics. 72 40

Agglutinin titres to Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, and Proteus vulgaris in the serum of patients with acute exacerbations of chronic bronchitis, patients producing mucoid sputum, and healthy controls were determined. Serological evidence of infection with H. influenzae was found in 38 of 57 patients with acute exacerbations, and Str. pneumoniae infection in 10 of the 57 patients, but was generally absent from healthy control subjects and from patiens producing mucoid sputum. No serological evidence of infection with other organisms named above was found to be associated with exacerbations of chronic bronchitis. Ten patients with acute exacerbations were without serological evidence of infection by any of the bacteria tested.
 ...
PMID:Agglutinin response to bacterial infection in acute exacerbations of chronic bronchitis. 80 63

Cefatrizine (SK&F 60771), a new orally-active semisynthetic cephalosporin antibiotic with broad-spectrum antibacterial activity, was compared with cephalexin and cefazolin for in vitro and in vivo antibacterial activity and pharmacokinetic behavior in laboratory animals. The average MIC values obtained with cefatrizine against gram-positive and gram-negative bacteria were superior to those obtained with cephalexin and somewhat poorer than those of cefazolin. In addition, a large percentage of the enterobacter and enterococcus isolates were found to be susceptible. Cefatrizine had a longer biological half-life and a higher peak serum level than either cefazolin or cephalexin when administered parenterally or orally to mice at 20 mg/kg. It had striking in vivo protective activity in mice infected with Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Hemophilus influenzae, Proteus morganii or Staphylococcus aureus reflecting its superior pharmacokinetic profile in this animal species. A variable pharmacokinetic response between animal species was observed when cefatrizine was administered either orally or parenterally to dogs, squirrel monkeys or rabbits.
 ...
PMID:Laboratory studies with cefatrizine (SK + F 60771), a new broad-spectrum orally-active cephalosporin. 80 25


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>